SCHEMBL5542227

SCHEMBL5542227

CC(C)(C)OC(=O)N1CCN(c2ccc(-c3ccccc3)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.65
ALDH1A1 P00352 2/20 0.64
MAPT P10636 2/20 0.64
LMNA P02545 1/20 0.64
NAMPT P43490 1/20 0.61
CKS1B P61024 2/20 0.59
SKP1 P63208 2/20 0.59
SKP2 Q13309 2/20 0.59
JAK2 O60674 1/20 0.58
JAK3 P52333 1/20 0.58
ESR2 Q92731 1/20 0.57
CTSS P25774 1/20 0.56
CTSK P43235 1/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
POLB P06746 1/20 0.55
SLC6A7 Q99884 1/20 0.55
PDK2 Q15119 1/20 0.55
ESRRB O95718 1/20 0.54
ESR1 P03372 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458887 0.91 GPR119 (0.76) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL5573222 0.89 MAPT (0.76) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL13279526 0.89 MAPT (0.64) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL13164532 0.88 GPR119 (0.61) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL941160 0.87 ALDH1A1 (0.62) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL11889756 0.87 MAPT (0.68) GPR119ALDH1A1MAPTNAMPTJAK2
SCHEMBL24990320 0.86 MAPT (0.61) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL2881177 0.86 GPR119 (0.62) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL942427 0.86 GPR119 (0.64) GPR119ALDH1A1MAPTLMNANAMPT
SCHEMBL5235594 0.86 GPR119 (0.69) GPR119ALDH1A1MAPTLMNANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GPR119 658/4885ALDH1A1 355/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.